Butterfly Network Inc

Butterfly Network CFO John N. Doherty sold 57,136 shares for approximately $375,000 on July 20, 2026, according to an SEC filing. The transaction was a non-discretionary sell-to-cover event mandated by company policy to satisfy tax obligations from vesting restricted stock units, reducing his direct holdings by 4% to 1,397,276 shares. The sale occurred after a year in which Butterfly Network shares returned 260%, with the company reaffirming full-year revenue guidance of $117 million to $121 million and an expected adjusted EBITDA loss of $21 million to $25 million. First-quarter revenue rose 25% to $26.5 million, gross margin widened to 69%, and the adjusted EBITDA loss narrowed to $6.1 million.

The global veterinary clinics market grew from $39.11 billion in 2025 to $41.7 billion in 2026, a 6.6% increase, and is projected to reach $54.32 billion by 2030 at a 6.8% compound annual growth rate, according to a new report from ResearchAndMarkets.com. Growth is driven by rising pet ownership, greater spending on companion animal care, and demand for advanced diagnostics and personalized treatments. North America was the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region. Key players include CVS Group plc, The Animal Medical Center, and Small Door Veterinary Inc., with recent innovations such as Butterfly Network's launch of the Butterfly iQ3 Vet Solution, a handheld semiconductor-based ultrasound system, and strategic moves like ARENA Veterinary Holding GmbH's acquisition of Star Veterinary Clinics LLC in May 2025.

Butterfly Network has commercially launched its Butterfly iQ+ and iQ3 handheld ultrasound devices and mobile application in Brazil through authorized distribution partners. The launch expands the company's international presence into Latin America's largest medical device market, where demand for portable diagnostic solutions is growing. Management noted that meeting Brazil's rigorous regulatory standards underscores the strength of its Ultrasound-on-Chip technology. The devices, already sold in the U.S. and multiple international regions, contributed to a 23% year-over-year increase in international revenues in the first quarter of 2026. Despite the announcement, Butterfly Network shares fell 3.2% on the day, though the stock has risen 102.1% year to date.

Butterfly Network's embedded partner Aleph Neuro has unveiled what it describes as the highest-resolution 3D images of the human brain captured non-invasively using Butterfly's Ultrasound-on-Chip platform. The announcement marks another validation of Butterfly Network's Embedded licensing and co-development business, extending the reach of its technology beyond traditional point-of-care imaging into emerging applications such as brain-computer interfaces. While the development is still at an early stage and is unlikely to have an immediate financial impact, it reinforces Butterfly Network's long-term growth prospects by showcasing the versatility of its platform and its ability to unlock future licensing opportunities. Aleph Neuro's approach combines Butterfly's Ultrasound-on-Chip technology with advanced imaging techniques to produce MRI-like brain images without invasive procedures or large, expensive MRI systems. The milestone comes shortly after another Butterfly Embedded partner unveiled a full-body ultrasound CT scanner, underscoring the versatility of the company's proprietary semiconductor-based ultrasound technology across diverse applications.

Butterfly Network commented on Midjourney's launch of a full-body imaging system, outlining its role in the scanner's underlying hardware and future scaling plans. The current prototype integrates 40 Ultrasound-on-Chip imaging modules per system under an existing co-development agreement, with future versions expected to use significantly more modules as the platform grows. CEO Joseph DeVivo called the system an extraordinary whole-body scanner that works without radiation or magnetic risk, using about half a million sensors and more than two petaflops of processing power. DeVivo said the device is designed for frequent use, allowing continuous monitoring of physiological changes, and noted that the prior agreement outlines up to $74 million in expected payments over five years.